Cannabis and cud
Browse the latest research linking medical marijuana / medicinal cannabis and cud.
Click on a study title below to open a new tab with full article, or click on a compound to see it's full list of research.
Compounds Topics Title Date
cannabis cud in humans via experiment (n=87) Threat Responsiveness as a Function of Cannabis and Alcohol Use Disorder Severity Jun 2019
Increasing levels of CUD symptomatology were associated with decreased responding to looming stimuli within regions, including rostral frontal and fusiform gyrus as well as the amygdala.
CBD appetite supress,cud in humans via trial (n=94) Cannabidiol Attenuates the Appetitive Effects of delta-9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis Aug 2010
Our findings suggest that CBD has potential as a treatment for cannabis dependence. The acute modulation of the incentive salience of drug cues by CBD may possibly generalize to a treatment for other addictive disorders.
Nabilone,Dronabinol cud in humans via placebo trial (n=14) Subjective, cognitive, and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers Jan 2012
Ingestion Method: nabilone (2, 4, 6, 8 mg), dronabinol (10, 20 mg)
Nabilone (4, 6, 8 mg) and dronabinol (10, 20 mg) increased ratings of feeling a good effect, a strong effect, and/or `high' relative to placebo; nabilone had a slower onset of peak subjective effects than dronabinol. Nabilone (6, 8 mg) modestly lowered psychomotor speed relative to placebo and dronabinol.
cannabis cud in humans via survey (n=29) Cannabis Withdrawal in Chronic, Frequent Cannabis Smokers during Sustained Abstinence within a Closed Residential Environment May 2014
The combined influence of residual/offset drug effects, withdrawal and craving was observed in chronic cannabis smokers during monitored abstinence. Abstinence symptoms were generally more intense in the initial phase, implying importance of early intervention in cannabis quit attempts. Sleep disturbance persisting for an extended period suggests that hypnotic medications could be beneficial in treating cannabis dependence.
CBD cud in humans via trial (n=20) Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial Mar 2018
Ingestion Method: 200mg oral daily
CBD was well tolerated with no reported side effects; however, participants retrospectively reported reduced euphoria when smoking cannabis. No impairments to cognition were found, nor were there deleterious effects on psychological function.
cannabis cud in humans via trial (n=15) Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers. Jul 2019
Ingestion Method: guanfacine (2 mg)
Action Pathway: A2A
The alpha-2a-adrenergic agonist, lofexidine, reduced cannabis withdrawal-related sleep disruption in the laboratory, but side effects (e.g. fatigue, hypotension) limit its utility as a treatment for cannabis use disorder.
cannabis cud in humans via survey Falling rates of marijuana dependence among heavy users. Oct 2018
Though it is unclear why, the risk of dependence formation among heavy marijuana users appear to have declined since 2002. Further research is warranted regarding explanations related to state marijuana policies, product forms, or social context.
cannabis cud via review Cannabis use disorder and suicide attempts in bipolar disorder: A meta-analysis May 2019
Cannabis use disorder and suicide attempts were weakly associated in bipolar disorder.
cannabis cud in humans via trial (n=302) Acute and long-term cannabis use among stimulant users: Results from CTN-0037 Stimulant Reduction Intervention using Dosed Exercise (STRIDE) Randomized Control Trial May 2019
For those who adhered to the exercise intervention, vigorous intensity, high dose exercise resulted in less cannabis use.
cannabis cud in humans via trial (n=37) A preliminary test of a brief intervention to lessen young adults' cannabis use: Episode-level smartphone data highlights the role of protective behavioral strategies and exercise. May 2019
Participants reduced their cannabis use by approximately 1 half of a standard joint per time point. The MET + CBT + Exercise condition reduced cannabis use to a greater degree than did the MET + CBT condition.
Sativex cud in humans via placebo trial (n=128) Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial. Jul 2019
This study demonstrates that cannabinoid agonist treatment, in this case using nabiximols, in combination with psychosocial interventions is a safe approach for reducing cannabis use among individuals with cannabis dependence who are seeking treatment.
cannabis cud in humans via trial (n=22) Guanfacine extended-release for cannabis use disorder: a pilot feasibility trial. Jul 2019
G-XR is a feasible treatment for CUDs, and should be evaluated further in an efficacy trial.
cannabis cud in humans via survey (n=39599) Integration of screening, assessment, and treatment for cannabis and other drug use disorders in primary care: An evaluation in three pilot sites Apr 2019
A pilot implementation of BHI to increase routine screening and assessment for SUDs was associated with increased new CUD diagnoses and a small increase in treatment of new other DUDs.